抗生素与SFGH（英文PPT）Antibiotics at SFGHPPT.ppt

Antibiotics at SFGH;Important Contacts and Info ;Overview;Beta-lactam antibiotics;Beta-lactams: Overview;Natural Penicillins;Commonly used penicillins;Penicillin/Beta-lactamase inhibitor combinations (BLIs);Penicillins: Places in therapy;1st Generation Cephalosporins;2nd generation Cephalosporins;3rd generation cephalosporins;Third-generation Cephalosporins:Problem Gram-negative Pathogens;4th Generation Cephalosporin Cefepime (Maxipime);Extended spectrum β-lactmases (ESBLs) ;ESBLs cont.;Cephalosporin places in therapy;Cephalosporin allergic potential;Carbapenems;Ertapenem ;Fluoroquinolones ;FluoroquinolonesSpectrum of Activity: Gram-positive;FluoroquinolonesSpectrum of Activity: Gram-negative;Quinolones: other pathogens;FQ Pharmacokinetics ;FQ Drug Interactions;Quinolone agents: place in therapy;;Gram-Negative Bacilli Resistance Associated With Fluoroquinolone Use ;2006 SFGH Inpatient Susceptibilities (Gram-negative pathogens);Anti-pseudomonal antibiotics;Comparative Antibiotics (SFGH 1 Day Therapy);Treatment of Community-Acquired PNA;HAP or VAP Suspected (All Disease Severity) ;Empiric Antibiotics for HAP Assess Risk Factors For Drug Resistant Pathogens;HAP/VAP: Empiric regimens;HAP/VAP: Empiric regimens;“Aspiration” Pneumonia;SFGH MRSA: Overview;PubMed Community-MRSA Articles;MRSA in San Francisco Hospitals;Current FDA-Approved Drug Treatments for MRSA infections;Vancomycin: Overview;Vancomcyin Kinetics/Dosing;Vancomycin Monitoring;Vancomycin: Adverse Effects ;Vancomycin for MRSA: Common Problems ;Relationship of MIC to Vancomycin Treatment Failures in MRSA Infections;S. aureus bacteremia;Tice, Honolulu;Empiric Treatment of Skin and Soft-Tissue Infections (SSTI) : Oral Treatment Options;MRSA Osteomyelitis;Final Thoughts;Contact Information